Bioatla, Inc. (BCAB) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. Bioatla, Inc. is a clinical-stage biopharmaceutical company developing conditionally active biologics (CABs) for solid tumor cancers. The company has no approved products and has not generated product revenue. As of June 30, 2025, the company had 58.7 million shares of common stock outstanding.
Key Financial Metrics
| Metric (in thousands) | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(18,711) | $(21,072) | $(34,045) | $(44,306) |
| Operating Expenses | $18,647 | $21,972 | $36,261 | $46,429 |
| Cash and Cash Equivalents | $18,207 (End of Period) | $61,662 (End of Period) | $18,207 (End of Period) | $61,662 (End of Period) |
| Net Cash Used in Operating Activities | N/A | N/A | $(30,408) | $(50,021) |
| Accumulated Deficit | $(520,084) | $(460,569) | $(520,084) | $(460,569) |
| Stockholders' Equity (Deficit) | $(16,745) | $31,370 | $(16,745) | $31,370 |
Material Changes vs. Prior Period
- Reduced Burn Rate: Net loss decreased by approximately 11% in Q2 2025 compared to Q2 2024 ($18.7M vs. $21.1M) and by 23% on a year-to-date basis ($34.0M vs. $44.3M).
- Expense Reductions: Total operating expenses declined due to a 30% workforce reduction implemented in March 2025 and a lease footprint reduction in June 2025. Research and Development (R&D) expenses decreased by $2.5M in Q2 and $9.0M YTD, driven by lower headcount, reduced stock-based compensation, and prioritization of clinical programs.
- Liquidity Decline: Cash and cash equivalents dropped from $49.0M at year-end 2024 to $18.2M at June 30, 2025, representing a net decrease of $30.8M over the six-month period.
- Warrant Liability: The company recorded a $1.6M gain on warrant liability for the six months ended June 30, 2025, due to changes in fair value, partially offsetting operating losses.
Guidance, Outlook, Risks, and Contingencies
- Going Concern: Management has concluded there is substantial doubt about the company's ability to continue as a going concern for at least 12 months from the issuance date. Current cash reserves ($18.2M) are estimated to fund operations only into the first half of 2026.
- Capital Needs: The company expects to continue incurring significant losses and will require substantial additional capital to fund clinical trials and operations. Future funding may come from equity/debt financings or collaborations.
- Nasdaq Delisting Risk: The company received a delisting determination from Nasdaq on August 6, 2025, for failing to meet the Minimum Bid Price Requirement ($1.00) and Minimum Stockholders' Equity Requirement ($10M). The company intends to appeal this determination.
- Restructuring: A corporate restructuring in March 2025 resulted in a 30% reduction in force. Restructuring costs of $0.6M were incurred in the first six months of 2025 and were fully paid out by Q2.
- Lease Modification: In June 2025, the company amended its lease to reduce space and extend the term, recognizing a new lease liability and right-of-use asset of approximately $6.0M.
Investor Verification Checklist
- Verify the status of the Nasdaq delisting appeal and the likelihood of regaining compliance with listing standards.
- Assess the timeline and probability of securing additional financing given the "substantial doubt" going concern warning and current cash runway.
- Review the progress of Phase 2 clinical trials for lead candidates (mecbotamab vedotin, ozuriftamab vedotin, evalstotug) to determine if data readouts will support future capital raises.
- Monitor the impact of the 30% workforce reduction on the company's ability to execute its clinical development plans.
- Check for any updates on the Context Therapeutics license agreement regarding BA3362, specifically the timing of potential milestone payments.